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The promyelocytic leukemia tumor suppressor gene (PML) critically regulates several cellu-
lar functions that oppose tumorigenesis such as oncogene-induced senescence, apoptosis,
the response to DNA damage and to viral infections. PML deficiency occurs commonly in
a broad spectrum of human cancers through mechanisms that involve its aberrant ubiqui-
tination and degradation. Furthermore, several viruses encode viral proteins that promote
viral replication through degradation of PML. These observations suggest that restoration
of PML should lead to potent antitumor effects or antiviral responses. In this review we
will summarize the mechanisms involved in PML degradation with the intent to highlight
novel therapeutic strategies to trigger PML restoration.
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INTRODUCTION
The promyelocytic leukemia tumor suppressor gene (PML) was
initially identified as a component of the PML-Retinoic Acid
Receptor Alpha (RARA) oncoprotein as a result of the chromoso-
mal translocation t (15;17) of acute promyelocytic leukemia (APL)
(de The et al., 1990; Goddard et al., 1991; Kakizuka et al., 1991;
Pandolfi et al., 1991).
The human PML gene is located on chromosome 15, and
consists of nine exons that generate several alternative spliced tran-
scripts. As a result, all of the PML isoforms contain a conserved
N-terminal region consisting of the RING, B-boxes, coiled-coil
(RBCC) motifs, and the SUMO Binding Domain (SBD), and they
all differ in the central and C-terminal regions (Fagioli et al., 1992;
Jensen et al., 2001).
Promyelocytic leukemia tumor suppressor gene concentrates
in distinct subnuclear structures known as PML-Nuclear Bodies
(PML-NB), also called PML Oncogenic Domains (POD), Nuclear
Domain 10 (ND10), or Kremer bodies (Bernardi and Pandolfi,
2007). PML-NBs are discrete highly dynamic nuclear foci with
an average diameter of 0.2–1µm. Typically, 5–30 PML-NBs are
present in most mammalian cells nuclei, depending on the cell
type and the cell cycle phase, while PML-NBs are disrupted and
dispersed in microspeckles in the leukemic blasts of APL patients
(Daniel et al., 1993; Dyck et al., 1994).
Promyelocytic leukemia tumor suppressor gene-nuclear bod-
ies have been implicated in gene transcription (both activation
and repression), apoptosis and cellular senescence, tumor sup-
pression, viral pathogenicity, and DNA repair (Seeler and Dejean,
1999; Zhong et al., 2000a; Regad and Chelbi-Alix, 2001; Dellaire
and Bazett-Jones, 2004; Bernardi and Pandolfi, 2007).
Pml null cells are devoid of PML-NBs: this observation led to
the conclusion that PML is the essential component of PML-NBs
(Wang et al., 1998a). Consistently, the functional properties of
PML and PML-NBs overlap. For instance, PML critically regulates
multiple tumor suppressive pathways such as oncogene-induced
senescence (OIS) and apoptosis (Wang et al., 1998a,b; Ferbeyre
et al., 2000; Pearson et al., 2000; Bernardi and Pandolfi, 2007;
Bernardi et al., 2008). Moreover, Pml inactivation in mice leads
to cancer susceptibility in several organs (Wang et al., 1998a;
Rego et al., 2001; Scaglioni et al., 2006; Trotman et al., 2006). In
humans, PML deficiency occurs commonly in a broad spectrum
of human cancers including lung, prostate and breast carcinoma,
lymphomas, CNS tumors, and germ cell tumors, through a mech-
anism that involves aberrant ubiquitin-mediated degradation
(Koken et al., 1995; Gurrieri et al., 2004a; Scaglioni et al., 2006).
Due to the pivotal role of PML in tumor suppression and other
important cellular functions, the understanding of the molecu-
lar mechanisms involved in its degradation have been the subject
of intense investigation. This review will focus on the mecha-
nisms involved in this process and will discuss their functional
significance.
PML FUNCTIONS
Several lines of evidence underscore the role of PML in tumor
suppression (Wang et al., 1998a; Rego et al., 2001; Scaglioni et al.,
2006; Trotman et al., 2006), senescence, and apoptosis (Wang et al.,
1998b; Ferbeyre et al., 2000; Guo et al., 2000; Pearson et al., 2000;
Bischof et al., 2002; Scaglioni et al., 2012). Moreover, PML has
been implicated in other important cellular functions, such as
neoangiogenesis (Bernardi et al., 2006), cell migration (Reineke
et al., 2010), the DNA damage response (Dellaire and Bazett-
Jones, 2004), antiviral defense (Geoffroy and Chelbi-Alix, 2011),
and most recently in the regulation of hematopoietic stem cells
(HSCs) maintenance (Ito et al., 2012) (Figure 1).
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FIGURE 1 | PML functions. PML plays several critical cellular functions,
such as apoptosis and senescence, neoangiogenesis, cell migration, DNA
damage response, antiviral defense, and hematopoietic stem cell
maintenance.
CELLULAR SENESCENCE
Replicative senescence is the phenomenon by which cells undergo
an irreversible cell cycle arrest, loosing the ability to divide and pro-
liferate. Several stresses have been implicated in the induction of
senescence, including oxidative damage, telomerase dysfunction,
DNA damage, and aberrant oncogene-dependent proliferative sig-
naling (Collado and Serrano, 2006, 2010; Campisi and d’Adda di
Fagagna, 2007).
Several laboratories demonstrated that PML is a key regula-
tor of oncogene-induced cellular senescence. PML achieves this
effect through several complementary and interconnected mecha-
nisms. Oncogenic K-RAS induces senescence in a p53-dependent
manner. In this context, PML is transcriptionally upregulated and
promotes the recruitment to PML-NBs of the p300/CBP tran-
scriptional co-activator, which in turn leads to p53 acetylation
and consequent transcriptional activation (Ferbeyre et al., 2000;
Pearson et al., 2000). Notably, PML itself is a p53 target gene
(de Stanchina et al., 2004). These observations led to the conclu-
sion that oncogenic K-RAS induces cellular senescence through a
feed-forward transcriptional mechanism that depends on the p53
tumor suppressor (de Stanchina et al., 2004).
Subsequently, it was also found that PML also induces senes-
cence via the retinoblastoma (Rb) pathway in human fibroblasts
(Mallette et al., 2004).
More recently, we showed that oncogenic K-RAS induces PML
upregulation even in p53 null cells. Under these conditions, the
PML 5′ untranslated mRNA region (5′ UTR) mediates selective
uploading of the PML mRNA onto polyribosomes and its selective
translation, leading to p53 independent PML upregulation. These
data suggest that selective protein translation plays an impor-
tant role in mediating an efficient oncogene-induced replicative
senescence response (Scaglioni et al., 2012).
APOPTOSIS
It is well established that PML promotes apoptosis. For instance,
Pml null thymocytes show a reduction of DNA damage-induced
apoptosis when compared to their wild type counterparts (Wang
et al., 1998b). This is, at least in part, due to the ability of PML
to physically interact with p53 regulating its transcriptional activ-
ity. These findings led to the conclusion that inactivation of PML
impairs the ability of p53 to induce expression of specific pro-
apoptotic and growth-inhibiting target genes such as p21 and
Bax. Furthermore, PML is required for Fas and caspase-dependent
apoptotic activity (Wang et al., 1998b; Guo et al., 2000).
Another function of PML in apoptosis has been associated to
the PML isoforms that are located in the cytoplasm. PML accu-
mulates in PML-NBs, however some PML isoforms have been
described in the cytoplasm (Lin et al., 2004). It was reported
that cytoplasmic PML aggregates in a macromolecular complex
with the 1,4,5-triphosphate receptor (IP3R), AKT, and the protein
phosphatase 2a (PP2a) at mitochondria-associated membranes
(MAMs). Here PML regulates IP3R-mediated Ca2+ release from
the endoplasmic reticulum with the consequent induction of
apoptosis (Giorgi et al., 2010).
NEOANGIOGENESIS
Promyelocytic leukemia tumor suppressor gene deficiency
increases neoangiogenesis in mouse models and its deficiency cor-
relates with increased vessel density in human cancers. Indeed,
PML deficiency increases pro-angiogenic factors such as vascular
endothelial growth factor (VEGF) and hypoxia-inducible factor
1 (HIF1). PML achieves this effect by repressing HIF1 transcrip-
tional activity, and controlling HIF1 accumulation by the negative
regulation of the AKT-mTOR pathway (Bernardi et al., 2006).
CELL MIGRATION
Promyelocytic leukemia tumor suppressor gene can negatively reg-
ulate the expression of the β1 integrins. Therefore, PML is involved
in the regulation of cell migration preventing metastasis (Reineke
et al., 2010).
DNA DAMAGE RESPONSE
Even though the mechanisms are still not completely clear, PML
has been shown to be involved in the regulation of the response to
DNA damage.
Promyelocytic leukemia tumor suppressor gene-nuclear bod-
ies have been proposed as highly dynamic structures in which
several DNA repair factors transit in order to be redistributed to
DNA damage foci. Accordingly, PML-NBs have been functionally
associated to several pathways regulating DNA repair, including
non-homologous end-joining repair (NHEJ),homologous recom-
bination repair (HR), as well as the alternative lengthening of
telomerases (ALT) (Dellaire and Bazett-Jones, 2004).
ANTIVIRAL DEFENSE
Several viral proteins interact with PML and PML-NBs (Everett,
2001). Numerous studies underline the role of PML and PML-NBs
in host antiviral response. For instance, interferon (IFN) stimula-
tion leads to PML upregulation promoting PML-NBs formation
(Chelbi-Alix et al., 1995; Regad and Chelbi-Alix, 2001; Geoffroy
and Chelbi-Alix, 2011). Finally, several DNA and RNA viruses,
such as herpes viruses and rabies viruses, encode proteins that
co-localize with PML disorganizing the PML-NBs. This observa-
tion suggests that viruses disrupt PML-NBs as a strategy to evade
Frontiers in Oncology | Molecular and Cellular Oncology March 2013 | Volume 3 | Article 60 | 2
Rabellino and Scaglioni Degradation of PML
cellular resistance mechanism to viral infections (Geoffroy and
Chelbi-Alix, 2011).
HEMATOPOIETIC STEM CELL MAINTENANCE
Asymmetric stem cell division is thought to be critical to ensure
self-renewal of the stem cells reservoir. Through this process stem
cells give rise to two daughter cells with different cellular fates:
one daughter cells will maintain the stem cell pool, while the sec-
ond daughter cells is programed to undergo differentiation. PML
has been recently involved in the maintenance of HSCs (Ito et al.,
2008) and in the regulation of asymmetric division of stem cells.
PML achieves this effect by regulating the Peroxisome Proliferator-
Activated Receptors (PPAR)-δ, which in turn promotes fatty acid
oxidation (FAO). In this setting, inactivation of PML, PPAR-δ,
or FAO results in symmetric HSCs division and loss of their
self-renewal capacities (Ito et al., 2012).
POST-TRANSLATIONAL MODIFICATION OF PML
Several post-translational modifications regulate PML activity.
These modifications are described below.
PHOSPHORYLATION
Promyelocytic leukemia tumor suppressor gene is phosphory-
lated at serine and tyrosine residues. For instance, the mitogen-
activated protein kinase Extracellular signal Regulated Kinases 2
(ERK2) has been shown to phosphorylate PML on several residues.
These modifications have been implicated in the degradation of
PML upon treatment with arsenic trioxide (ATO) (Hayakawa and
Privalsky, 2004). Ataxia-Telangiectasia and RAD3-Related (ATR)
and Checkpoint Kinase 2 (CHK2) also phosphorylate PML in a
DNA damage-dependent way (Bernardi et al., 2004; Yang et al.,
2006). Moreover, phosphorylation by Casein Kinase 2 (CK2)
induces PML degradation in a proteasomal/ubiquitin-dependent
way (Scaglioni et al., 2006).
SUMOylation
SUMOylation is one of the most intensely studied post-
translational modifications of PML and of PML-RARA. Both
SUMO1 and SUMO2/3 covalently bind PML (Kamitani et al.,
1998a,b; Fu et al., 2005); in addition, PML binds to the SUMO
E2-ligases UBC9 (Borden, 2002). SUMOylation of PML and PML-
RARA have been associated to seemingly opposed activities. For
example, it was reported that SUMOylation of PML facilitates the
assembly of the PML-NBs promoting tumor suppressive responses
and that SUMOylation of PML-RARA is essential for its leuke-
mogenic activities (Zhong et al., 2000b; Zhu et al., 2005; Shen
et al., 2006), however other reports indicated that, in cells exposed
to ATO, SUMOylation of PML and PML-RARA promote their
ubiquitin-mediated degradation (Lallemand-Breitenbach et al.,
2008; Tatham et al., 2008). More recently, we demonstrated that the
Protein Inhibitor of Activated STAT 1 (PIAS1) SUMO E3-ligase
SUMOylates PML and its oncogenic counterpart PML-RARA.
This process leads to the ubiquitin-mediated degradation of both
PML and PML-RARA (Rabellino et al., 2012). Taken together,
these studies have led to the working hypothesis that poly SUMOy-
lation represents a molecular switch that triggers the ubiquitin-
mediated degradation of both PML and PML-RARA (de The and
Chen, 2010; de The et al., 2012). We will discuss later in this review
the critical data that support this hypothesis.
ACETYLATION
Another PML post-translational modification is acetylation. PML
acetylation on the lysines 487 and 515 has been proposed to
be associated with the increase of PML SUMOylation, suggest-
ing that the acetylated form of PML is preferentially SUMOy-
lated. PML acetylation is enhanced by the Histone deacetylase
(HDAC) inhibitor trichostatin A (TSA), suggesting a role of PML
acetylation in TSA-induced apoptosis (Hayakawa et al., 2008).
UBIQUITINATION
Finally, PML can be also ubiquitinated. PML ubiquitination plays
an essential role in the regulation of PML functions and activ-
ity. Importantly, aberrant PML ubiquitination and degradation
has been reported to occur in various types of human tumors.
For these reasons, PML ubiquitination and degradation will be
discussed in greater detail later in this review.
PML DEGRADATION
Promyelocytic leukemia tumor suppressor gene plays a pivotal
role in tumor suppression, apoptosis, and senescence, and in the
control of viral infections. For these reasons, PML degradation
would provide a selective advantage in tumor initiation and pro-
gression or a strategy used by viruses to evade the antiviral cellular
mechanisms.
The first evidence of the disruption of PML activity came from
the study of PML-RARA in APL, where PML tumor suppressive
functions are disrupted due to the fusion with the RARA (Rego
et al., 2001). In addition, complete or partial loss of PML protein
expression has been observed in multiple human cancer types,
such as prostate and colon adenocarcinoma, breast carcinoma,
lymphoma, CNS tumors, and germ cell tumors (Koken et al., 1995;
Gambacorta et al., 1996; Gurrieri et al., 2004a; Chen et al., 2012).
The PML gene rarely undergoes somatic mutations in tumors
other than APL and its promoter does not undergo epigenetic
silencing (Gurrieri et al., 2004a). Instead, deregulated ubiquiti-
nation appears to be the common mechanism accounting for
PML loss in cancer. Several mechanisms have been reported to
be involved in PML ubiquitination (Fanelli et al., 2004; Scaglioni
et al., 2006; Lallemand-Breitenbach et al., 2008; Louria-Hayon
et al., 2009; Reineke et al., 2010; Lim et al., 2011; Yuan et al., 2011;
Chen et al., 2012; Rabellino et al., 2012; Wolyniec et al., 2012). We
will review their biological significance in tumorigenesis and in
viral infection.
PML-RARA DEGRADATION
Historically, the first evidence of PML degradation was obtained in
APL leukemic blasts treated with ATO. The t (15;17) of APL is a rec-
iprocal and balanced translocation giving rise to both PML-RARA
and a RARA-PML fusion proteins. As a result of this transloca-
tion, both PML and RARA are reduced to hemizygosity. Extensive
work from several laboratories has characterized the properties
and mechanisms of action of PML-RARA (Scaglioni and Pandolfi,
2007; Ablain and de The, 2011).
In this disease, treatment with ATO leads to complete APL
remission. Molecular studies demonstrated that ATO treatment
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leads to ubiquitin-proteasomal degradation of PML-RARA lead-
ing to the conclusion that this property of ATO is responsible for
its therapeutic effect (Wang and Chen, 2008; de The and Chen,
2010; de The et al., 2012).
Arsenic trioxide induces PML-RARA ubiquitination and con-
sequent proteasomal degradation through a mechanism that
involves the SUMOylation of its PML moiety. This process has
been recently unveiled in detail. Mechanistically, ATO binds
directly the RING domain of the PML moiety of PML-RARA,
facilitating its oligomerization and SUMOylation (Zhang et al.,
2010); moreover, ATO induces the production of reactive oxy-
gen species that allow the formation of PML-RARA-multimers,
which aggregate into PML-NBs, the cellular compartment where
their degradation ultimately occurs (Lallemand-Breitenbach et al.,
2001, 2008; Tatham et al., 2008; Jeanne et al., 2010; Rabellino et al.,
2012).
It was reported that SUMOylation at lysine 160 of the PML
moiety is essential for the proteasome-targeting of PML-RARA
(Lallemand-Breitenbach et al., 2001), however the SUMOylation
of other lysines may be involved in the process as well (Rabellino
and Scaglioni, unpublished data). The groups of R. Hay and H. de
Thé clarified the molecular mechanism that allows the degradation
of SUMOylated PML and PML-RARA. In cells treated with ATO
the ubiquitin E3-ligase Ring-Finger protein 4 (RNF4) is rapidly
recruited into the PML-NBs where it recognizes poly-SUMOylated
chains covalently bound to PML and PML-RARA, leading to
their ubiquitination and consequent degradation (Lallemand-
Breitenbach et al., 2008; Tatham et al., 2008). RNF4 is a member
of the SIM/RING-finger family. These proteins can directly couple
the ubiquitin machinery to poly-SUMOylated substrates through
their SIM domain. Due to this peculiar characteristic, this fam-
ily of protein is indicated as SUMO Targeted Ubiquitin Ligases
(STUBbLs) (Sun et al., 2007).
The SUMO E3-ligase that mediates the SUMOylation of PML
and PML-RARA has been elusive until recently. We showed that
PIAS1 is a PML and PML-RARA SUMO E3-ligase. Ectopic expres-
sion of PIAS1 increases PML-RARA SUMOylation and strikingly
increases the ability of ATO to degrade PML-RARA. Knock down
of PIAS1 in NB4 cells, an APL cell line that recapitulates the
effects elicited by ATO in primary APL cells (Roussel and Lanotte,
2001), significantly reduces the ability of ATO to degrade PML-
RARA causing a significant resistance to ATO-induced apoptosis
(Rabellino et al., 2012). It should be noted that PIAS1 mediates
also the degradation of PML in cells treated with ATO, however
this event is apparently inconsequential in APL. This is prob-
ably due to the fact that PML-RARA is the dominant driving
force of APL (Scaglioni and Pandolfi, 2007; de The and Chen,
2010).
Collectively, these findings elegantly describe the molecular
mechanisms involved in PML-RARA degradation (Figure 2),
rising the opportunity to improve APL therapy.
Even though the molecular mechanism of ATO-dependent
PML-RARA degradation has been described in great detail, sev-
eral questions are still open. For example, we demonstrated that
ATO stimulates PIAS1 activity, increasing its ability to SUMOylate
PML-RARA (Rabellino et al., 2012). However, the mechanism of
activation of PIAS1 is still unknown, and whether ATO triggers
FIGURE 2 | ATO-dependent PML-RARA SUMOylation and degradation.
ATO triggers PML-RARA degradation leading to APL remission. This process
requires the PIAS1 SUMO E3-ligase and the ubiquitin E3-ligase RNF4. ATO
is thought to directly bind to the PML moiety of PML-RARA. This event
causes a conformational change that allows PML-RARA poly-SUMOylation
and its interaction with RNF4. ATO, arsenic trioxide; S, SUMOylation; Ub,
ubiquitination.
PIAS1 activity through direct binding to its RING domain (as is
the case for RNF4) or through other mechanisms is still unknown.
Furthermore, the model described above is at first sight at
odds with the longstanding observation that SUMOylation of
PML-RARA at lysine 160 is required for APL leukemogenesis
(Zhu et al., 2005). This observation is consistent with our finding
that, in the absence of ATO, PIAS1-mediated SUMOylation up-
regulates PML-RARA and is not sufficient to induce its degrada-
tion (Rabellino et al., 2012). However ATO dramatically enhances
PML-RARA poly-SUMOylation. Thus, it is possible that ATO
maximally activates PIAS1 or that it promotes the recruitment of
yet to be identified proteins that enhance the processivity of PIAS1
allowing the synthesis of longer SUMO chains. With unpublished
experiments we discovered that in the presence of ATO PIAS1
SUMOylates sites in the PML moiety other than K160, but whether
or not these residues have a biological role in determining the
response to ATO treatment is not yet known. These questions will
keep the aficionados of this field busy in the future.
CK2-DEPENDENT PML DEGRADATION
The group of Pandolfi was the first to report an extensive analysis
of PML status in human cancer. These investigators determined
that PML is commonly lost in several cancers types. However, this
group did not detect somatic mutations or promoter methyla-
tion events that justified PML deficiency (Gurrieri et al., 2004a,b).
This analysis has been confirmed with large mutational stud-
ies in human cancer (for example the Sanger Cosmic database).
Subsequently, it was reported that PML is degraded in immor-
talized and tumor-derived cell lines through a mechanisms that
involves proteasomal dependent ubiquitin-mediated degradation.
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Mutational analysis of PML revealed the presence of a C-terminal
phosphodegron essential for PML ubiquitination (Scaglioni et al.,
2006).
Casein Kinase 2 is a highly conserved and ubiquitously
expressed serine/threonine kinase (Pinna, 2002). CK2 is frequently
activated in a wide range of human cancers and its expression
in transgenic mice can induce mammary tumor formation and
lymphomas (Seldin and Leder, 1995; Landesman-Bollag et al.,
2001).
Casein Kinase 2 promotes direct phosphorylation of PML on
the serine 517 (note that this nomenclature applies to PML iso-
form IV lacking exon 5) located in the PML degron, leading to PML
ubiquitin-mediated degradation. Accordingly, PML mutants that
cannot be phosphorylated by CK2 show a resistance to ubiquitin-
mediated degradation and increased tumor suppressive functions.
In this process, the activity of the p38 MAPK is required in order to
activate CK2, and pharmacological inhibition of CK2 enhances the
PML tumor suppressive activity in vivo. Finally, it has been shown
an inverse correlation between the level of PML proteins and
CK2 kinase activity in human lung cancer specimens (Scaglioni
et al., 2006). These observations lead to the hypothesis that the
phosphorylation of the serine 517 on the PML degron by CK2
is required for the interaction with a specific ubiquitin E3-ligase,
but its identity is still unknown. In conclusion, since it has been
shown that CK2 gene amplification is a marker of poor prognosis
in NSCLC (O-charoenrat et al., 2004), a therapy that specifically
inhibits CK2 may be particularly effective by inducing restora-
tion of PML and its tumor suppressive functions. Notably, several
specific CK2 inhibitors have demonstrated antitumor activity in
preclinical trials. Moreover, a CX-4945, a specific pharmacologic
inhibitor of CK2, is being tested in early clinical trials in cancer
patients: these drugs could be instrumental in restoring PML in
cancer cells (Hanif et al., 2010; Siddiqui-Jain et al., 2010; Ferguson
et al., 2011; Sarno et al., 2011; Cozza et al., 2012).
This work described how oncogenic stress through the acti-
vation of CK2 is able to induce PML degradation in cancer cells
both in vitro and in vivo. However, some links are missing from
this working model. For example, the ubiquitin E3-ligase involved
in the PML ubiquitination is still unknown. Moreover, the initial
report, did not determine whether SUMOylation, which has been
involved in PML degradation in cells exposed to ATO, is involved
in CK2 mediated PML degradation.
PIAS1-DEPENDENT PML DEGRADATION
SUMOylation has been implicated in the regulation of both
PML and PML-RARA (Lallemand-Breitenbach et al., 2001, 2008;
Tatham et al., 2008). Moreover, SUMOylation has been impli-
cated in PML-NBs formation (Zhong et al., 2000b; Shen et al.,
2006; Bernardi and Pandolfi, 2007) and in regulation of PML-
mediated apoptosis (Hayakawa and Privalsky, 2004). These obser-
vations indicate that SUMOylation plays an important role in PML
regulation. We hypothesized that the discovery of the SUMO E3-
ligase that mediates PML SUMOylation would reveal functional
and mechanistic insights onto the regulation of PML biological
properties.
We tackled this question by identifying PML interacting pro-
teins with the yeast two-hybrid screening. We found that PIAS1
and PIASxα interact with PML, promoting its SUMOylation.
Surprisingly, we found that only PIAS1-dependent PML SUMOy-
lation leads to PML ubiquitination and degradation; on the con-
trary, PIASxα leads to PML stabilization. Consistent with these
results, PIAS1 silencing in a panel of NSCLC cell lines up-regulates
PML protein levels and leads to a significant PML-dependent
anti-proliferative effects. In this context, its notable that PIAS1-
dependent SUMOylation increases the interaction between CK2
and PML, which in turns promotes PML phosphorylation at ser-
ine 517 and degradation. Based on these findings, we propose a
model in which PIAS1-dependent PML SUMOylation is required
for the CK2/PML interaction and phosphorylation of the PML
degron (Figure 3A).
Finally, we found that PIAS1 and PML expression are inversely
correlated in NSCLC cell lines and in primary lung cancers
(Rabellino et al., 2012) and prostate (Rabellino and Scaglioni,
unpublished data). Consistently with these studies, we also found
that the PIAS1 gene is amplified in a subset of NSCLC cell lines
(Rabellino et al., 2012). These data indicate that PIAS1 promotes
tumorigenesis through downregulation of PML.
The SUMO E3-ligases PIASs have been mainly implicated in
the regulation of innate immunity through epigenetic mechanisms
(Liu et al., 2004, 2010; Shuai and Liu, 2005; Rytinki et al., 2009).
Moreover, it has been suggested that PIAS1 may regulate oncogenic
networks through its ability to inhibit tumor suppressors such as
p53, BRCA1, and STAT1 (Schmidt and Muller, 2002; Galanty et al.,
2009; Wu and Chiang, 2009). Therefore, our work reveled a novel
function of PIAS1.
Taken together, these findings show an elaborated cellular net-
work, in which SUMOylation, CK2, and a not yet identified
ubiquitin E3-ligase cooperate in order to trigger PML degrada-
tion (Figure 3B). For instance, is tempting to speculate that any of
the PML ubiquitin E3-ligase that have been described so far may
play a role in this process. However, there are no reports in the
literature that support this hypothesis. Finally, the identification
of specific inhibitors able to target PIAS1 activity may provide a
strategic alternative to inhibit PML degradation.
The finding that PML, PIAS1, and CK2 physically interact
suggests that PIAS1 and CK2 may cross talk. This hypothesis is sup-
ported by the observation that CK2 phosphorylates PIAS1 in vitro
(Stehmeier and Muller, 2009). Hence, future studies should deter-
mine whether CK2 phosphorylates PIAS1 also in cells and whether
this event has any functional relevance.
It also remains to be determined whether other members
of the PIAS family are PML SUMO E3-ligases and whether
they regulate any of the activities ascribed to PML. Further-
more, the ubiquitin E3-ligase(s) involved in the final process
of PML ubiquitination and degradation in cancer cells is still
unknown and future investigations should be directed to its/their
identification. Finally, it is not clear yet if the ubiquitination
occurs on PML itself, or on the SUMO chains as described for
PML-RARA (Lallemand-Breitenbach et al., 2008; Tatham et al.,
2008).
HYPOXIA-DEPENDENT PML UBIQUITINATION
The ability to induce neoangiogenesis is one of the hallmarks
of cancer (Hanahan and Weinberg, 2011), and the transcription
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FIGURE 3 | CK2 and PIAS1-dependent PML degradation. (A)
PIAS1-dependent PML SUMOylation is required for the phosphorylation of
the PML degron by CK2 and subsequently degradation. (B) PIAS1, together
with CK2 and an unknown ubiquitin E3-ligase cooperate in order to lead to
PML degradation. S, SUMOylation; Ub, ubiquitination; P, phosphorylation.
Arrows indicate possible cross-talks.
factor HIF1 is a key regulator of the adaption of cancer cells to
conditions of hypoxia (Semenza, 2010).
The protein complex KLHL20-Cul3-ROC1 is an ubiquitin E3-
ligase involved in the regulation of HIF signaling through the
poly-ubiquitination and degradation of the Death-associated Pro-
tein Kinase (DAPK), a mediator of IFN-induced cell death. The
KLHL20-dependent DAPK ubiquitination is suppressed in cells
stimulated with IFN, which induce the KLHL20 sequestration into
the PML-NBs (Lee et al., 2010).
It was recently reported that KLHL20 cooperates with the
Cyclin-dependent Kinase 1/2 (CDK1/2) and the Peptidyl-prolyl
cis/trans isomerase Pin1 to mediate PML degradation in hypoxic
conditions. Under hypoxia, HIF1 induces the transcription of
KLHL20, increasing its accumulation into PML-NBs. In this
scenario, two different post-translational modifications of PML
make possible its interaction with KLHL20: first, PML iso-
form I (PML-I) is phosphorylated on serine 518 by CDK1
and CDK2. Second, phosphorylated PML-I undergoes Pin1-
dependent prolyl-isomerization. Notably, the authors reported
that hypoxia-dependent PML degradation, not only attenuates
PML tumor suppressor activity, but also participates to a feed-
back mechanism that maximizes the production of HIF1 during
hypoxic stress. These data are consistent with the observation
that in human prostate cancers PML inversely correlates with
the over expression of HIF1, KLHL20, and Pin1 (Yuan et al.,
2011).
These data led to the conclusion that the KLH20-Cul3 com-
plex is an ubiquitin E3-ligase for PML. However, the authors
found that in this case, SUMOylation is dispensable for PML
ubiquitin-mediated degradation. Therefore, it is not clear whether
the KLH20-Cul3 complex is mainly responsible for PML degra-
dation in conditions of hypoxia or whether it plays a significant
role also in regulating the role of PML in other conditions of onco-
genic stress. Moreover, it remains to be determined in which tumor
types this phenomenon may occur. Thus, future experiments will
be needed to determine the significance of the KLH20-Cul3 com-
plex to PML degradation in vivo. We reason that these studies
will benefit from studies with genetically engineered mouse mod-
els to determine the biological significance of these phenomena
in vivo.
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SIAH1/2-DEPENDENT PML AND PML-RARA DEGRADATION
SIAH proteins are RING-finger-containing ubiquitin E3-ligases
involved in the degradation of transcriptional regulators, com-
ponents of the cell cycle machinery, and proteins involved in
tumorigenesis (House et al., 2009; Lipkowitz and Weissman, 2011).
The mammalian SIAH1 and SIAH2 have been reported to interact
with PML and PML-RARA inducing their degradation. More in
detail, SIAH1 and SIAH2 interact with the RING domain of PML
and PML-RARA triggering their proteasome-mediated degrada-
tion. Accordingly, overexpression of SIAH1 and SIAH2 in APL cell
lines, partially restore PML-RARA-induced differentiation block
in APL blast through the degradation of PML-RARA (Fanelli et al.,
2004).
The conclusions of this study are limited by the fact that these
data were obtained with proteins ectopically expressed in cell lines
cultured in vitro. Moreover, it is noteworthy that overexpression
of SIAH1 and SIAH2 in PML-RARA expressing cells only partially
rescues cells differentiation, raising the possibility that PML-RARA
is not a physiological substrate of SIAH1 and SIAH2. Studies with
genetically engineered mice would be needed to test the role of
SIAH1 and SIAH2 in APL.
ERK2/Pin1-DEPENDENT PML DEGRADATION
Pin1 is over expressed in a wide range of human tumors (Wulf
et al., 2005). Due to its ability to interact with different proteins
families, Pin1 has been found to be able to affect phosphoryla-
tion status, protein-protein interactions, cellular localization, and
protein stability (Galat, 2003). It was reported that in breast can-
cer cell lines Pin1 binds PML, inducing its downregulation. In
this scenario, phosphorylation of PML on two key serine residues
(serine 403 and serine 505) by the kinase ERK2 facilitates the
recruitment of Pin1. In this study, inhibition of ERK2 with spe-
cific drugs or siRNA decreased the interaction between PML
and Pin1, leading to upregulation of PML and PML-NBs forma-
tion. Conversely, stimulation of ERK2 with growth factor such
as Epidermal Growth Factor (EGF) increases phosphorylation of
PML and its downregulation (Reineke et al., 2008; Lim et al.,
2011).
The MAP-kinase ERK2 is widely involved in eukaryotic sig-
nal transduction (Roskoski, 2012). Several extracellular signal-
ing can activates the MAP-kinase cascade, including aberrant
signaling from oncogenic stress or stimuli. From this point of
view, a better understanding of the mechanisms involved in
ERK2/Pin1-dependent PML degradation may provide new insight
in the development of specific drugs targeted to prevent PML
degradation.
This study is however limited by the fact that it was performed
in a limited set of cultured breast cancer cell lines. Moreover, this
study did not present any data obtained in genetically defined
mouse cancer models or in primary human specimens. Further-
more, it remains to be addressed whether the CDK1/2-Pin1 and the
ERK2/Pin1 mechanisms to ubiquitinate PML are complementary,
mutually exclusive, or tumor type specific. Thus, future studies
will need to determine whether these data are relevant in naturally
occurring tumors. Should this be the case, it is noteworthy that
several chemical inhibitors of MEK1 (the upstream regulator of
ERK2) exist; thus, this strategy could be tested in clinic.
E6AP-MEDIATED PML UBIQUITINATION
E6AP was the first mammalian ubiquitin E3-ligase to be iden-
tified. Initially, E6AP was identified as the ubiquitin E3-ligase
that cooperates with the human papillomavirus (HPV) protein
E6 to promote p53 degradation (Talis et al., 1998). E6AP interacts
with PML, partially residing into the PML-NBs. It was reported
that E6AP overexpression leads to PML downregulation in an
proteasome/ubiquitin-dependent way; accordingly E6AP null cells
show higher expression of PML proteins (Louria-Hayon et al.,
2009).
DNA damage triggers accumulation of PML and increases
PML-NBs formation (Bernardi and Pandolfi, 2007). Notably,
E6AP deficient cells show an increase of DNA damage-dependent
apoptosis, due to an accumulation of PML into to the nucleus
with a consequent increase of PML-dependent response. Finally,
E6AP is also involved in ATO-dependent PML degradation
(Louria-Hayon et al., 2009).
The role of E6AP in PML degradation has also been investi-
gated in B-cell lymphomagenesis. Partial loss of E6AP attenuates
MYC-induced B-cell lymphomagenesis. In this model, tumor sup-
pression is achieved by the induction of cellular senescence but not
apoptosis. Accordingly, partial loss of E6AP leads to PML restora-
tion and subsequently induction of PML-dependent senescence.
Indeed, B-cell lymphomas lacking EA6P express elevated level of
PML and PML-NBs, with a concomitant increase of markers of
senescence. Accordingly, E6AP expression levels are elevated in
43% of human Burkitt lymphoma derived cells lines and in 60%
of primary human Burkitt lymphomas (Wolyniec et al., 2012).
Taken together, these data indicate an important role of E6AP
in PML degradation. Noteworthy, E6AP may contribute to ATO-
induced PML degradation, and further analysis should be done to
understand if E6AP and RNF4 interact in the promotion of PML
degradation or whether they participate in distinct processes.
Promyelocytic leukemia tumor suppressor gene protein expres-
sion is frequently lost in non-Hodgkin lymphomas (Gurrieri et al.,
2004a) and the expression of EA6P is elevated in about 60% of
human Burkitt’s lymphoma. The model provided gives a molecu-
lar explanation of the down-regulation of PML in non-Hodgkin
lymphomas, suggesting a direct connection between E6AP expres-
sion and PML degradation in this disease. Importantly, these
data are supported by a correlation with in vivo model and
human specimens, providing confidence in their relevance in vivo.
Finally, these findings strongly suggest that restoration of PML
expression in non-Hodgkin lymphomas may provide an attractive
therapeutic approach.
VIRUS-DEPENDENT PML DEGRADATION
Viral infections often result in PML-NBs disruption and PML
degradation (Everett, 2001).
Historically, the first evidence of the interaction between viruses
and PML came from the observation that infection of cells with
Herpes virus 1 (HSV-1) led to the rapid disruption of the PML-
NBs (Maul et al., 1993). Further analysis confirmed that the HSV-1
regulatory protein ICP0 is sufficient to induce PML degradation
in a proteasome-dependent way (Everett and Maul, 1994; Chelbi-
Alix and de The, 1999). Similar to HSV-1, infection with human
Cytomegalovirus (HCMV) causes PML-NBs disruption: in this
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process, the viral protein IE1 is necessary and sufficient to pro-
mote this effect. However in this case, IE1 is not involved in
PML degradation, but in its chromatin redistribution (Ahn et al.,
1998).
Another example of viral protein able to disrupt the PML-
NBs is BZLF1, from the Epstein–Barr virus (EBV). In this case,
expression of BZLF1 alone is sufficient to induce PML-NBs dis-
ruption and the loss of the SUMOylated forms of PML. Interest-
ingly, BZLF1 can be SUMOylated, and it has been reported that
BZLF1 competes with PML for its SUMOylation. This observa-
tion suggests that if a cellular component of the SUMOylation
machinery is limiting, BZLF1 could inhibit PML SUMOylation
by the direct competition with the limiting factor (Adamson and
Kenney, 2001).
Taken together, these data suggest that the disruption of PML-
NBs and the degradation of PML are an important step for the
lytic cycle of all herpes virus (Adamson and Kenney, 2001; Everett,
2001).
Other viral infections have also been association with the dis-
ruption of PML-NBs (Everett, 2001; Geoffroy and Chelbi-Alix,
2011). For example, it has been suggested that HIV1 infection
triggers delocalization of PML into the cytoplasm, however, other
groups have found that HIV1 does not modify PML-NBs (Turelli
et al., 2001; Geoffroy and Chelbi-Alix, 2011). Therefore, the role
of HIV in the regulation of PML-NBs and PML is still unsettled.
The antiviral activity of PML resides on its ability to re-organize
the PML-NBs in order to activate an efficient antiviral response.
For this reason, it has been suggested that the ability of certain
virus to interact with the PML-NBs formation inducing PML
down-regulation is a strategy to evade the antiviral effect of PML
(Geoffroy and Chelbi-Alix, 2011). Thus, a better understanding
of the molecular mechanisms involved in virus-dependent PML
degradation may provide new insight in a more efficient antivi-
ral therapies or strategies to prevent viral infections. Given the
advances in our understanding of the mechanism that lead to
PML ubiquitin-mediated degradation in cancer cells, future stud-
ies will undoubtedly test whether viruses utilize the same cellular
machinery that cancer cells use.
CONCLUSION
Promyelocytic leukemia tumor suppressor gene is a key tumor
suppressor and its inactivation through aberrant degradation has
been found in several human cancers types. Moreover, PML down-
regulation plays an important role in promoting viral infections.
A large body of literature indicates that PML is rarely mutated and
FIGURE 4 | Mechanisms of PML degradation. A complex molecular
network is involved in PML degradation: these mechanisms include several
post-translational modifications that trigger PML ubiquitination and
degradation, resulting in the loss of its tumor suppressive activity or
antiviral properties. S, SUMOylation; P, phosphorylation.
its downregulation occurs predominately at the post-translational
level. Several pathways have been reported to trigger PML ubiqui-
tination and degradation (Figure 4). This situation is reminiscent
of the degradation of other tumor suppressors, which is often
achieved through multiple context-dependent networks. It will
be important in the future to determine which mechanisms are
the critical regulators on PML degradation in specific cancers
in vivo. We reason that these studies will most likely benefit from
the availability of faithful and genetically defined mouse cancer
models and correlative studies in primary human samples. We
are looking forward to these developments with the expectation
that pharmacologic targeting of the networks that control PML
degradation will lead to specific therapies for cancer and for several
viral infections.
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